GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) ...

The recommendation by the CHMP should now result in approval of Arexvy in the broader age range in February next year, and ...

There is underreporting of adverse effects from vaccines; but, in the vast majority of cases, the side effects from the ...

You are correct that there is underreporting of adverse effects from vaccines; however, in the vast majority of cases, the ...

Research led by the Veterans Affairs Portland Health Care System in Portland, Oregon, found that a single dose of respiratory ...

A number of diseases tend to peak in the winter, thanks to indoor gatherings that help germs spread. The list includes not ...

You recently posted a couple of articles about the respiratory syncytial virus (RSV) vaccine and the benefits versus ...

In the third quarter, our revenue were $1 billion, driven by sales of our fully approved vaccines, Spikevax, mNEXSPIKE, ...

The Food and Drug Administration is investigating whether coronavirus vaccines are linked to deaths of adults, part of an ...

According to DataM Intelligence, the Respiratory Syncytial Virus (RSV) Market Size reached USD 1.95 billion in 2024 and is projected to advance to USD 4.54 billion by 2033, expanding at a strong CAGR ...

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to expand seasonal vaccine franchise from three to up to six approved products ...